Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA warns about sexual enhancement supplement

This article was originally published in The Tan Sheet

Executive Summary

The agency warns consumers Aug. 25 about TimeOut Capsules because they contain an undeclared ingredient. Hydroxythiohomosildenafil is similar to sildenafil, the FDA-approved ingredient in Pfizer's prescription Viagra, and may interact with nitrates to cause unsafe drops in blood pressure. "TimeOut is labeled as '100% natural' and consumers may mistakenly assume the product is harmless and poses no health risk," FDA said. The TimeOut warning is the latest in what has become a stready stream of alerts and recall announcements for so-called weight-loss and male enhancement supplements found to contain undeclared drugs (1"The Tan Sheet" Aug. 23, 2010, In Brief)

You may also be interested in...

Weight-loss, male enhancement drugs recalled

The maker of Mr. Magic Male Enhancer from Don Wands sexual enhancement product voluntarily launches a recall after FDA determined the presence of undeclared ingredients. Glow Industries said Aug. 18 it recalled Mr. Magic because it contains hydroxythiohomosildenafil and sulfoaildenafil, analogues of sildenafil, an Rx ingredient for treatment of erectile dysfunction that may react unsafely with nitrates. Separately on Aug. 19, J&H Besta expanded a previous recall of its Slim-30 Herb Supplement weight-loss product, the subject of a recent FDA consumer advisory, because it contains undeclared desmethyl sibutramine, similar in structure to the appetite suppressant drug sibutramine (1"The Tan Sheet" July 26, 2010, In Brief)

QUOTED. 28 January 2020. Steven Falowski.

Abbott is encouraged by results from two studies of its Proclaim XR neurostimulation system for chronic pain, presented at the annual North American Neuromodulation Society (NANS) meeting in Las Vegas. See what Steven Falowski of Neurosurgical Associates of Lancester in Pennsylvania said about it here.

Japan Phase III Failure To End Mono Opdivo Hopes In Ovarian Cancer?

While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts